SEC14L1: A Potential Drug Target and Biomarker (G6397)

Target Name: SEC14L1

NCBI ID: G6397

SEC14L1

SEC14L1: A Potential Drug Target and Biomarker

Secretory Granule-associated protein 14 (SEC14L1) is a protein that is expressed in various cell types, including epithelial, endothelial, and pericytoplasmic cells, as well as muscle and liver cells. It is a member of the secretory granule-associated protein (SGAP) family and is known for its role in intracellular signaling and protein sorting.

SEC14L1 has been identified as a potential drug target due to its unique structure and the involvement of various signaling pathways. The protein is composed of 214 amino acid residues and has a calculated molecular mass of 21.1 kDa. It is expressed in a variety of tissues and cells and is involved in several cellular processes, including cell signaling, protein sorting, and intracellular signaling.

One of the key functions of SEC14L1 is its role in intracellular signaling. The protein is involved in several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These signaling pathways are involved in a variety of cellular processes, including cell growth, differentiation, and survival.

SEC14L1 is also involved in protein sorting, which is a critical process in intracellular signaling. The protein is involved in the sorting of intracellular proteins to the endoplasmic reticulum (ER) and other intracellular organelles. This sorting process is critical for the delivery of proteins to their intended destination and is a key component of intracellular signaling.

In addition to its role in intracellular signaling and protein sorting, SEC14L1 is also involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. The protein is involved in the formation of tight junctions, which are critical for the regulation of cell-cell communication and the maintenance of tissue structure. It is also involved in the regulation of cell migration and invasion, which are critical for the development and progression of cancer.

The potential drug target for SEC14L1 is based on its involvement in several cellular processes that are associated with the development and progression of cancer.SEC14L1 has been shown to be involved in the regulation of cell cycle progression, apoptosis, angiogenesis, and inflammation. In addition, the protein has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

SEC14L1 has also been shown to be involved in the regulation of protein synthesis and degradation. The protein is involved in the regulation of protein synthesis by the translation of mRNAs, as well as the regulation of protein degradation by the 26S proteasome. These processes are critical for the maintenance of cellular homeostasis and the regulation of cellular processes.

In conclusion, SEC14L1 is a protein that is involved in several cellular processes that are critical for the development and progression of cancer. Its unique structure and the involvement of various signaling pathways make it an attractive potential drug target. Further research is needed to fully understand the role of SEC14L1 in cellular processes and its potential as a drug target.

Protein Name: SEC14 Like Lipid Binding 1

Functions: May play a role in innate immunity by inhibiting the antiviral RIG-I signaling pathway. In this pathway, functions as a negative regulator of RIGI, the cytoplasmic sensor of viral nucleic acids. Prevents the interaction of RIGI with MAVS/IPS1, an important step in signal propagation (PubMed:23843640). May also regulate the SLC18A3 and SLC5A7 cholinergic transporters (PubMed:17092608)

The "SEC14L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC14L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets